Parametric Response Mapping as an Imaging Biomarker in Lung Transplant Recipients
Authors:
- Elizabeth A. BelloliEBElizabeth A. Belloli
- Irina DegtiarIDIrina Degtiar
- Xin WangXWXin Wang
- Gregory A. YanikGYGregory A. Yanik
- Linda J. StuckeyLSLinda J. Stuckey
- Stijn E. VerledenSVStijn E. Verleden
- Ella A. KazerooniEKElla A. Kazerooni
- Brian D. RossBRBrian D. Ross
- Susan MurraySMSusan Murray
- Craig J. GalbánCGCraig J. Galbán
- Vibha N. LamaVLVibha N. Lama
- 1 April 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 195 (7) , 942-952
Abstract
Rationale: The predominant cause of chronic lung allograft failure is small airway obstruction arising from bronchiolitis obliterans. However, clinical methodologies for evaluating presence and degree of small airway disease are lacking. Objectives: To determine if parametric response mapping (PRM), a novel computed tomography voxel-wise methodology, can offer insight into chronic allograft failure phenotypes and provide prognostic information following spirometric decline. Methods: PRM-based computed tomography metrics quantifying functional small airways disease (PRMfSAD) and parenchymal disease (PRMPD) were compared between bilateral lung transplant recipients with irreversible spirometric decline and control subjects matched by time post-transplant (n = 22). PRMfSAD at spirometric decline was evaluated as a prognostic marker for mortality in a cohort study via multivariable restricted mean models (n = 52). Measurements and Main Results: Patients presenting with an isolated decline in FEV1 (FEV1 First) had significantly higher PRMfSAD than control subjects (28% vs. 15%; P = 0.005), whereas patients with concurrent decline in FEV1 and FVC had significantly higher PRMPD than control subjects (39% vs. 20%; P = 0.02). Over 8.3 years of follow-up, FEV1 First patients with PRMfSAD greater than or equal to 30% at spirometric decline lived on average 2.6 years less than those with PRMfSAD less than 30% (P = 0.004). In this group, PRMfSAD greater than or equal to 30% was the strongest predictor of survival in a multivariable model including bronchiolitis obliterans syndrome grade and baseline FEV1% predicted (P = 0.04). Conclusions: PRM is a novel imaging tool for lung transplant recipients presenting with spirometric decline. Quantifying underlying small airway obstruction via PRMfSAD helps further stratify the risk of death in patients with diverse spirometric decline patterns.Keywords
This publication has 45 references indexed in Scilit:
- Computed tomography–based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progressionNature Medicine, 2012
- Survival after Bronchiolitis Obliterans Syndrome among Bilateral Lung Transplant RecipientsAmerican Journal of Respiratory and Critical Care Medicine, 2010
- The parametric response map is an imaging biomarker for early cancer treatment outcomeNature Medicine, 2009
- Long-term Survival After Lung Transplantation Depends on Development and Severity of Bronchiolitis Obliterans SyndromeThe Journal of Heart and Lung Transplantation, 2007
- Course of FEV1 after Onset of Bronchiolitis Obliterans Syndrome in Lung Transplant RecipientsAmerican Journal of Respiratory and Critical Care Medicine, 2007
- A class of rank test procedures for censored survival dataBiometrika, 1982
- Generalized Linear ModelsJournal of the Royal Statistical Society. Series A (General), 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Individual Comparisons by Ranking MethodsBiometrics Bulletin, 1945
- THE PROBABLE ERROR OF A MEANBiometrika, 1908